Assessment of Quality of Life and Treatment Outcomes of Patients with Persistent Postchemotherapy Alopecia

Azael Freites-Martinez, Donald Chan, Vincent Sibaud, Jerry Shapiro, Gabriella Fabbrocini, Antonella Tosti, Juhee Cho, Shari Goldfarb, Shanu Modi, Devika Gajria, Larry Norton, Ralf Paus, Tessa Cigler, Mario E. Lacouture

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

Importance: Persistent alopecia occurs in a subset of patients undergoing chemotherapy, yet the quality of life (QOL) of these patients and their response to therapy have not been described in a large patient cohort. Objective: To characterize the clinical presentation of patients with persistent chemotherapy-induced alopecia (pCIA) or endocrine therapy-induced alopecia after chemotherapy (EIAC) and their QOL and treatment outcomes. Design, Setting, and Participants: A retrospective multicenter cohort of 192 women with cancer treated with cytotoxic agents who received a clinical diagnosis of persistent alopecia (98 with pCIA and 94 with EIAC) between January 1, 2009, and July 31, 2017, was analyzed. All patients were from the dermatology service in 2 comprehensive cancer centers and 1 tertiary-care hospital. Data on demographics, chemotherapy regimens, severity, clinical patterns, and response to hair-growth promoting agents were assessed. Data from the Hairdex questionnaire were used to assess the QOL of patients with alopecia. Main Outcomes and Measures: The clinical presentation, response to dermatologic therapy, and QOL of patients with pCIA were assessed and compared with those of patients with EIAC. Results: A total of 98 women with pCIA (median age, 56.5 years [range, 18-83 years]) and 94 women with EIAC (median age, 56 years [range, 29-84 years]) were included. The most common agents associated with pCIA were taxanes for 80 patients (82%); the most common agents associated with EIAC were aromatase inhibitors for 58 patients (62%). Diffuse alopecia was predominant in patients with pCIA compared with patients with EIAC (31 of 75 [41%] vs 23 of 92 [25%]; P =.04), with greater severity (Common Terminology Criteria for Adverse Events, version 4.0, grade 2) among patients with pCIA (29 of 75 [39%] vs 12 of 92 [13%]; P <.001). A negative emotional effect was reported by both groups. After treatment with topical minoxidil or spironolactone, moderate to significant improvement was observed for 36 of 54 patients with pCIA (67%) and for 32 of 42 patients with EIAC (76%). Conclusions and Relevance: Persistent chemotherapy-induced alopecia is frequently more severe and diffuse when compared with EIAC, and both groups of patients experienced a negative effect. A modest benefit was observed with dermatologic therapy. Additional studies are warranted to develop effective strategies for prevention and effective therapy for pCIA and EIAC.

Original languageEnglish (US)
JournalJAMA dermatology
DOIs
StatePublished - Jan 1 2019

    Fingerprint

ASJC Scopus subject areas

  • Dermatology

Cite this

Freites-Martinez, A., Chan, D., Sibaud, V., Shapiro, J., Fabbrocini, G., Tosti, A., Cho, J., Goldfarb, S., Modi, S., Gajria, D., Norton, L., Paus, R., Cigler, T., & Lacouture, M. E. (2019). Assessment of Quality of Life and Treatment Outcomes of Patients with Persistent Postchemotherapy Alopecia. JAMA dermatology. https://doi.org/10.1001/jamadermatol.2018.5071